
    
      This is a multicenter phase 2 study of belantamab mafodotin on participants with
      plasmablastic lymphoma and ALK+ large B-cell lymphoma.The research study procedures include
      screening for eligibility, and study treatment, including evaluations and follow up visits.

        -  This research study involves the study drug belantamab mafodotin.

        -  Participants may receive the study treatment until progression or intolerance, and will
           be followed up to 2 years.

        -  It is expected that about 25 people will take part in this research study.

      This research study is a Phase II clinical trial. Phase II clinical trials test the safety
      and effectiveness of an investigational drug to learn whether the drug works in treating a
      specific disease. "Investigational" means that the drug is being studied.

      The U.S. Food and Drug Administration (FDA) has not approved belantamab mafodotin as a
      treatment for any disease. This study drug is investigational, and it is not known whether
      participants will benefit from taking belantamab mafodotin.
    
  